With the acquisition of Spyre Therapeutics, Aeglea shifts focus to the development of a world-class inflammatory bowel disease portfolio.
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease (IBD). Spyre is the second spinout of Paragon Therapeutics and is advancing a robust portfolio that harnesses both proven and novel mechanisms of action for addressing IBD. The company’s two parallel lead programs—SPY001 and SPY002—target a4b7 and TL1A, respectively, and build upon the validation of these targets by existing commercial- and clinical-stage antibody therapeutics.
IBD causes chronic inflammation of the digestive tract and can lead to diarrhea, rectal bleeding, abdominal pain, fatigue and weight loss. Symptoms can range from mild to life-threatening. There are approximately 1.7 million IBD patients in the U.S. and biologics are the preferred modality for moderate-to-severe patients due to a superior benefit-risk profile. The IBD global market, which includes Crohn’s disease and ulcerative colitis, is estimated to surpass $29 billion by 2028, representing a significant and growing opportunity.